Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Income from Continuing Operations (2018 - 2025)

Serina Therapeutics (SER) has disclosed Income from Continuing Operations for 8 consecutive years, with 6405000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 15.07% to 6405000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24235000.0 through Dec 2025, down 37.9% year-over-year, with the annual reading at 19215000.0 for FY2025, 71.46% down from the prior year.
  • Income from Continuing Operations hit 6405000.0 in Q4 2025 for Serina Therapeutics, roughly flat from 6398000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 65000.0 in Q4 2023 to a low of 6405000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 3230700.0 across 5 years, with a median of 2562500.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 102.36% in 2023 and later crashed 8663.08% in 2024.
  • Year by year, Income from Continuing Operations stood at 2262000.0 in 2021, then fell by 22.02% to 2760000.0 in 2022, then surged by 102.36% to 65000.0 in 2023, then plummeted by 8663.08% to 5566000.0 in 2024, then fell by 15.07% to 6405000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SER at 6405000.0 in Q4 2025, 6398000.0 in Q3 2025, and 5574000.0 in Q2 2025.